Fig. 4From: Soluble cytotoxic T-lymphocyte–associated antigen 4 (sCTLA-4) as a potential biomarker for diagnosis and evaluation of the prognosis in GliomaSurvival curves for PFS for all patients with glioma. Survival analysis was according to sCTLA-4 levels during therapy, with blue indicating high sCTLA-4 levels (> 189.64 pg/ml) and red denoting low sCTLA-4 levels (≤189.64 pg/ml) (p < 0.05, log-rank test)Back to article page